MAP2K7 and neoplasm: Activation of the cell cycle pathway in response to MEK inhibition, evidenced by the increase of downstream effector proteins such as p-Rb, was found in cells with increased cell death and tumor shrinkage when MEK and CDK4,6 inhibitors were used.